Shield Therapeutics (LON:STX) Shares Down 2.3% – Should You Sell?

Shares of Shield Therapeutics plc (LON:STX) traded down 2.3% on Wednesday . The company traded as low as GBX 10 and last traded at GBX 10.50. 1,713,937 shares changed hands during mid-day trading, an increase of 11% from the average session volume of 1,549,834 shares. The stock had previously closed at GBX 10.75.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reaffirmed a “buy” rating and set a GBX 15 target price on shares of Shield Therapeutics in a report on Friday, November 7th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of GBX 15.

Shield Therapeutics Stock Performance

The stock has a market cap of £111.49 million, a PE ratio of -5.25 and a beta of 1.42. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The stock has a 50-day moving average of GBX 9.35 and a 200 day moving average of GBX 7.18.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.